Serum Peptidome Patterns of Colorectal Cancer Based on Magnetic Bead Separation and MALDI-TOF Mass Spectrometry Analysis

Overview

Journal J Biomed Biotechnol

Specialty Biology

Date 2012 Oct 24

PMID 23091368

Citations 8

Authors

Nai-Jun Fan

Chun-Fang Gao

Xiu-Li Wang

Guang Zhao

Qing-Yin Liu

Yuan-Yao Zhang

Bao-Guo Cheng

Affiliations

Soon will be listed here.

Abstract

Background. Colorectal cancer (CRC) is one of the most common cancers in the world, identification of biomarkers for early detection of CRC represents a relevant target. The present study aims to determine serum peptidome patterns for CRC diagnosis. Methods. The present work focused on serum proteomic analysis of 32 health volunteers and 38 CRC by ClinProt Kit combined with mass spectrometry. This approach allowed the construction of a peptide patterns able to differentiate the studied populations. An independent group of serum (including 33 health volunteers, 34 CRC, 16 colorectal adenoma, 36 esophageal carcinoma, and 31 gastric carcinoma samples) was used to verify the diagnostic and differential diagnostic capability of the peptidome patterns blindly. An immunoassay method was used to determine serum CEA of CRC and controls. Results. A quick classifier algorithm was used to construct the peptidome patterns for identification of CRC from controls. Two of the identified peaks at m/z 741 and 7772 were used to construct peptidome patterns, achieving an accuracy close to 100% (>CEA, P < 0.05). Furthermore, the peptidome patterns could differentiate validation group with high accuracy. Conclusions. These results suggest that the ClinProt Kit combined with mass spectrometry yields significantly higher accuracy for the diagnosis and differential diagnosis of CRC.

Citing Articles

Circulating proteins as predictive and prognostic biomarkers in breast cancer.

Veyssiere H, Bidet Y, Penault-Llorca F, Radosevic-Robin N, Durando X Clin Proteomics. 2022; 19(1):25.

PMID: 35818030 PMC: 9275040. DOI: 10.1186/s12014-022-09362-0.

The Activation of Prothrombin Seems to Play an Earlier Role than the Complement System in the Progression of Colorectal Cancer: A Mass Spectrometry Evaluation.

Beitia M, Romano P, Larrinaga G, Solano-Iturri J, Salis A, Damonte G Diagnostics (Basel). 2020; 10(12).

PMID: 33322644 PMC: 7763171. DOI: 10.3390/diagnostics10121077.

Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome.

Santambrogio L, Rammensee H Immunogenetics. 2018; 71(3):203-216.

PMID: 30343358 PMC: 6377345. DOI: 10.1007/s00251-018-1093-z.

Serum peptidome profiling for the diagnosis of colorectal cancer: discovery and validation in two independent cohorts.

Wang H, Luo C, Zhu S, Fang H, Gao Q, Ge S Oncotarget. 2017; 8(35):59376-59386.

PMID: 28938643 PMC: 5601739. DOI: 10.18632/oncotarget.19587.

Weak cation exchange magnetic beads coupled with matrix-assisted laser desorption ionization-time of flight-mass spectrometry in screening serum protein markers in osteopenia.

He W, Liang B, Shi Z, Li X, Li C, Shi X Springerplus. 2016; 5(1):679.

PMID: 27347465 PMC: 4899343. DOI: 10.1186/s40064-016-2276-4.

References

Compton C, Greene F . The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004; 54(6):295-308. DOI: 10.3322/canjclin.54.6.295. View

Sui W, Huang L, Dai Y, Chen J, Yan Q, Huang H . Proteomic profiling of renal allograft rejection in serum using magnetic bead-based sample fractionation and MALDI-TOF MS. Clin Exp Med. 2010; 10(4):259-68. DOI: 10.1007/s10238-010-0094-5. View

Issaq H, Xiao Z, Veenstra T . Serum and plasma proteomics. Chem Rev. 2007; 107(8):3601-20. DOI: 10.1021/cr068287r. View

Ciccolallo L, Capocaccia R, Coleman M, Berrino F, Coebergh J, Damhuis R . Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut. 2005; 54(2):268-73. PMC: 1774819. DOI: 10.1136/gut.2004.044214. View

Du J, Yang S, Lin X, Bu L, Nan Y, Huo S . Use of anchorchip-time-of-flight spectrometry technology to screen tumor biomarker proteins in serum for small cell lung cancer. Diagn Pathol. 2010; 5:60. PMC: 2955651. DOI: 10.1186/1746-1596-5-60. View

Smith R, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley O . Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2011; 61(1):8-30. DOI: 10.3322/caac.20096. View

Chinello C, Gianazza E, Zoppis I, Mainini V, Galbusera C, Picozzi S . Serum biomarkers of renal cell carcinoma assessed using a protein profiling approach based on ClinProt technique. Urology. 2009; 75(4):842-7. DOI: 10.1016/j.urology.2009.09.050. View

West-Norager M, Kelstrup C, Schou C, Hogdall E, Hogdall C, Heegaard N . Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 847(1):30-7. DOI: 10.1016/j.jchromb.2006.09.048. View

Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A . Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008; 358(20):2107-16. DOI: 10.1056/NEJMoa0707064. View

10.

Liu L, Shan B, Tian Z, Sang M, Ai J, Zhang Z . Potential biomarkers for esophageal carcinoma detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem Lab Med. 2010; 48(6):855-61. DOI: 10.1515/CCLM.2010.138. View

11.

Navare A, Zhou M, McDonald J, Noriega F, Sullards M, Fernandez F . Serum biomarker profiling by solid-phase extraction with particle-embedded micro tips and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom. 2008; 22(7):997-1008. PMC: 2665883. DOI: 10.1002/rcm.3462. View

12.

Cho W . Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer. 2007; 6:25. PMC: 1852117. DOI: 10.1186/1476-4598-6-25. View

13.

Whiteaker J, Zhao L, Zhang H, Feng L, Piening B, Anderson L . Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem. 2007; 362(1):44-54. PMC: 1852426. DOI: 10.1016/j.ab.2006.12.023. View

14.

Yao N, Chen H, Lin H, Deng C, Zhang X . Enrichment of peptides in serum by C(8)-functionalized magnetic nanoparticles for direct matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis. J Chromatogr A. 2008; 1185(1):93-101. DOI: 10.1016/j.chroma.2008.01.047. View

15.

Fan N, Gao C, Wang X . Identification of Regional Lymph Node Involvement of Colorectal Cancer by Serum SELDI Proteomic Patterns. Gastroenterol Res Pract. 2012; 2011:784967. PMC: 3255105. DOI: 10.1155/2011/784967. View

16.

Edwards B, Ward E, Kohler B, Eheman C, Zauber A, Anderson R . Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2009; 116(3):544-73. PMC: 3619726. DOI: 10.1002/cncr.24760. View

17.

Dai Y, Hu C, Wang L, Huang Y, Zhang L, Xiao X . Serum peptidome patterns of human systemic lupus erythematosus based on magnetic bead separation and MALDI-TOF mass spectrometry analysis. Scand J Rheumatol. 2010; 39(3):240-6. DOI: 10.3109/03009740903456292. View

18.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

19.

Cheng A, Chen L, Chien K, Chen Y, Chang J, Wang H . Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem. 2005; 51(12):2236-44. DOI: 10.1373/clinchem.2005.052324. View

20.

Shin S, Cazares L, Schneider H, Mitchell S, Laronga C, John Semmes O . Serum biomarkers to differentiate benign and malignant mammographic lesions. J Am Coll Surg. 2007; 204(5):1065-71. DOI: 10.1016/j.jamcollsurg.2007.01.036. View